文献速递传染病防控与疫情报告卫生政策与健康促进

低风险或无疑似流行病学关联人群的猴痘病毒检测挑战——美国,2022年

Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox - United States, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-09-09

自2022年5月以来美国约2万例猴痘病例,全球约90国暴发主要影响男男性行为者。CDC的NVO特异性PCR为诊断主要工具,高敏感但批次污染可致假阳性。本报告描述3例无流行病学关联或已知风险因素的不典型皮疹患者,基于晚Ct值≥34被误诊为猴痘,后续检测均未确诊,促成CDC指南更新。

要点

  • 对无流行病学关联或风险因素者,晚Ct值(Ct≥34)结果应重新提取并复检。
  • NVO PCR高敏感,但同批次污染可致假阳性,需结合临床与流病信息判读。
  • CDC可对复杂或不典型病例提供额外病毒种/分支特异性PCR及血清学检测。

核心结论

  • 对于无流行病学关联或已知风险因素、或不满足临床标准(或这些信息未知)的患者,实验室科学家应重新提取并复检晚Ct值标本(基于本报告,推荐Ct≥34)。
  • CDC可对复杂病例(包括表现不典型或可疑者)提供咨询,并可进行额外的病毒种和分支特异性PCR检测及抗正痘病毒血清学检测。

研究设计与样本

  • 本报告为病例报告,描述3例有不典型皮疹且无猴痘病例流行病学关联或已知风险因素的患者。

主要发现

  • 3例患者基于晚Ct值≥34被诊断为猴痘,但后续检测均未确诊猴痘。
  • 初次诊断后,患者接受了抗病毒治疗(即tecovirimat),其密切接触者接受了JYNNEOS疫苗暴露后预防(PEP)。

关键数值与推荐

  • CDC已开发五项实时聚合酶链反应(PCR)检测用于从皮损标本中检测正痘病毒。
  • CDC的非天花正痘病毒(NVO)特异性PCR检测已获美国食品药品监督管理局510(k)许可。
  • 该检测于2000年代初在实验室响应网络(LRN)内实施。
  • PCR检测(NVO及其他正痘病毒实验室开发检测[LDT])是猴痘诊断的主要工具。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since May 2022, approximately 20,000 cases of monkeypox have been identified in the United States, part of a global outbreak occurring in approximately 90 countries and currently affecting primarily gay, bisexual, and other men who have sex with men (MSM) (1). Monkeypox virus (MPXV) spreads from person to person through close, prolonged contact; a small number of cases have occurred in populations who are not MSM (e.g., women and children), and testing is recommended for persons who meet the suspected case definition* (1). CDC previously developed five real-time polymerase chain reaction (PCR) assays for detection of orthopoxviruses from lesion specimens (2,3). CDC was granted 510(k) clearance for the nonvariola-orthopoxvirus (NVO)-specific PCR assay by the Food and Drug Administration. This assay was implemented within the Laboratory Response Network (LRN) in the early 2000s and became critical for early detection of MPXV and implementation of public health action in previous travel-associated cases as well as during the current outbreak (4-7). PCR assays (NVO and other Orthopoxvirus laboratory developed tests [LDT]) represent the primary tool for monkeypox diagnosis. These tests are highly sensitive, and cross-contamination from other MPXV specimens being processed, tested, or both alongside negative specimens can occasionally lead to false-positive results. This report describes three patients who had atypical rashes and no epidemiologic link to a monkeypox case or known risk factors; these persons received diagnoses of monkeypox based on late cycle threshold (Ct) values ≥34, which were false-positive test results. The initial diagnoses were followed by administration of antiviral treatment (i.e., tecovirimat) and JYNNEOS vaccine postexposure prophylaxis (PEP) to patients' close contacts. After receiving subsequent testing, none of the three patients was confirmed to have monkeypox. Knowledge gained from these and other cases resulted in changes to CDC guidance. When testing for monkeypox in specimens from patients without an epidemiologic link or risk factors or who do not meet clinical criteria (or where these are unknown), laboratory scientists should reextract and retest specimens with late Ct values (based on this report, Ct ≥34 is recommended) (8). CDC can be consulted for complex cases including those that appear atypical or questionable cases and can perform additional viral species- and clade-specific PCR testing and antiorthopoxvirus serologic testing.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Minhaj FS, Petras JK, Brown JA, et al. Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36074752. doi:10.15585/mmwr.mm7136e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。